FDA Approves First PARP Inhibitor for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
June 04, 2026
FDA Approves First PARP Inhibitor Rucaparib for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Charles Ryan, MD
Alicia Morgans and Charles Ryan highlight the breaking news that the Food and Drug Administration approved the first PARP Inhibitor for men with metastatic castration-resistant prostate cancer and a deleterious BRCA mutation.
FDA Approves First PARP Inhibitor Rucaparib for Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a Deleterious BRCA Mutation
Breaking News - Press Release
Clovis Oncology, Inc. (NASDAQ: CLVS), announced that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Wassim Abida, MD, Ph.D.
Wassim Abida provides a roadmap for molecular genetic subtyping in prostate cancer with the main goal of targeting the right therapies for progressing patients.
Results from TRITON2: Treatment of mCRPC with Rucaparib
Alan H. Bryce, MD
Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency.
